At the heart of Ad Scientiam's project is a conviction: measuring and monitoring the evolution of serious and disabling diseases on a continuous basis and in real life is essential for better management. We make visible these evolutions, until now undetectable, through the design and clinical validation of digital biomarkers. This scientific and technological challenge should enable each patient to be an active participant in their own illness and allow healthcare professionals to offer more individualized and therefore more efficient care. Ad Scientiam thus participates in the development of future treatments and in reducing the societal and economic impact of diseases. Hospital institutions such as the Brain Institute (ICM) and pharmaceutical companies such as Biogen, Janssen, Roche, Pfizer, Vertex and Novartis have already trusted us. In 2018, Ad Scientiam launched MSCopilot®, the first and only CE-marked software medical device for the self-assessment of multiple sclerosis patients. New devices are currently being validated in neuroscience, rare diseases and mental disorders.